Davis Polk partner and White Collar Criminal Defense and Government Investigations Group co-head Angela Burgess will be will be among the speakers at ACI's 12th Annual Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry. Burgess will be a panelist on “The DOJ’s New Corporate Enforcement Policy: An Analysis of Initial Impacts, Results and How Life Sciences Companies Should Assess Risk” panel. Topics discussed will include:
- How the implications of voluntary self-disclosure have changed in the wake of the new policy
- How the new corporate enforcement policy is factoring into companies’ decisions on whether or not to self-disclose
- How companies are evaluating the presumption of declination
- The enhanced value of cooperation
- The importance of individual vs. corporate accountability
- What impact the new corporate enforcement policy could have on potential whistleblowers’ motivation to step forward with an allegation
- The FCPA guidance’s practical meaning of “aggravating circumstances”
- The importance and meaning of “recidivism”
- Eligibility for declination in the case of a previous offense
- When a previous investigation didn’t result in a penalty but a DPA, declination or other corporate integrity agreement with specific compliance conditions attached
The program will be held June 18-19, 2018, in New York.
For more information, please visit the event website.